Green3Bio, Inc.
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers. (NCT04711161) | Green3Bio, Inc. | 2020-12-21 |
Track Green3Bio, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.